{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T11:18:02Z","timestamp":1774005482895,"version":"3.50.1"},"reference-count":43,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2015,10,1]],"date-time":"2015-10-01T00:00:00Z","timestamp":1443657600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neuroscience Letters"],"published-print":{"date-parts":[[2015,10]]},"DOI":"10.1016\/j.neulet.2015.08.054","type":"journal-article","created":{"date-parts":[[2015,9,3]],"date-time":"2015-09-03T02:32:49Z","timestamp":1441247569000},"page":"156-160","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":28,"special_numbering":"C","title":["Anti-annexin antibodies, cholesterol levels and disability in multiple sclerosis"],"prefix":"10.1016","volume":"606","author":[{"given":"Chiara","family":"Mandoj","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rosaria","family":"Renna","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Domenico","family":"Plantone","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Isabella","family":"Sperduti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giovanni","family":"Cigliana","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura","family":"Conti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tatiana","family":"Koudriavtseva","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.neulet.2015.08.054_bib0005","first-page":"435","article-title":"Liver X receptors, nervous system, and lipid metabolism","volume":"36","author":"Cermenati","year":"2013","journal-title":"J. Endocrinol. Invest."},{"key":"10.1016\/j.neulet.2015.08.054_bib0010","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1111\/ene.12162","article-title":"Cholesterol affects retinal nerve fiber layer thickness in patients with multiple sclerosis with optic neuritis","volume":"20","author":"Kardys","year":"2013","journal-title":"Eur. J. Neurol."},{"key":"10.1016\/j.neulet.2015.08.054_bib0015","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1186\/1742-2094-8-127","article-title":"Serum lipid profiles are associated with disability and MRI outcomes in multiple sclerosis","volume":"8","author":"Weinstock-Guttman","year":"2011","journal-title":"J. Neuroinflammation"},{"key":"10.1016\/j.neulet.2015.08.054_bib0020","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.1177\/1352458514533162","article-title":"An adverse lipid profile is associated with disability and progression in disability, in people with MS","volume":"20","author":"Tettey","year":"2014","journal-title":"Mult. Scler."},{"key":"10.1016\/j.neulet.2015.08.054_bib0025","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/S0304-3940(03)00667-0","article-title":"Decreased levels of the brain specific 24S-hydroxycholesterol and cholesterol precursors in serum of multiple sclerosis patients","volume":"347","author":"Teunissen","year":"2003","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.neulet.2015.08.054_bib0030","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1177\/1352458513499421","article-title":"Oxysterols and cholesterol precursors correlate to magnetic resonance imaging measures of neurodegeneration in multiple sclerosis","volume":"20","author":"van de Kraats","year":"2014","journal-title":"Mult. Scler."},{"key":"10.1016\/j.neulet.2015.08.054_bib0035","doi-asserted-by":"crossref","first-page":"2213","DOI":"10.1016\/S0140-6736(13)62242-4","article-title":"Effect of high-dose simvastatin on brain atrophy and disability in secondary progressive multiple sclerosis (MS-STAT): a randomised, placebo-controlled, phase 2 trial","volume":"383","author":"Chataway","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.neulet.2015.08.054_bib0040","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1155\/2013\/567162","article-title":"New markers of early cardiovascular risk in multiple sclerosis patients: oxidized-LDL correlates with clinical staging","volume":"34","author":"Palavra","year":"2013","journal-title":"Dis. Markers"},{"key":"10.1016\/j.neulet.2015.08.054_bib0045","doi-asserted-by":"crossref","first-page":"e65184","DOI":"10.1371\/journal.pone.0065184","article-title":"Involvement of oxidative stress in occurrence of relapses in multiple sclerosis: the spectrum of oxidatively modified serum proteins detected by proteomics and redox proteomics analysis","volume":"8","author":"Fiorini","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.neulet.2015.08.054_bib0050","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1016\/j.autrev.2008.04.018","article-title":"Oxidation of LDL and its clinical implication","volume":"7","author":"Matsuura","year":"2008","journal-title":"Autoimmun. Rev."},{"key":"10.1016\/j.neulet.2015.08.054_bib0055","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1186\/1471-2377-7-36","article-title":"Clinical and neuroimaging correlates of antiphospholipid antibodies in multiple sclerosis: a preliminary study","volume":"7","author":"Bidot","year":"2007","journal-title":"BMC Neurol."},{"key":"10.1016\/j.neulet.2015.08.054_bib0060","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.1007\/s10072-014-1823-4","article-title":"High frequency of antiphospholipid antibodies in relapse of multiple sclerosis: a possible indicator of inflammatory-thrombotic processes","volume":"35","author":"Koudriavtseva","year":"2014","journal-title":"Neurol. Sci."},{"key":"10.1016\/j.neulet.2015.08.054_bib0065","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1179\/1743132812Y.0000000076","article-title":"Anti-phospholipid antibodies are associated with response to interferon-beta1a treatment in MS: results from a 3-year longitudinal study","volume":"34","author":"Zivadinov","year":"2012","journal-title":"Neurol. Res."},{"key":"10.1016\/j.neulet.2015.08.054_bib0070","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1002\/ana.22366","article-title":"Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria","volume":"69","author":"Polman","year":"2011","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.neulet.2015.08.054_bib0075","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1111\/j.1600-0404.1997.tb00300.x","article-title":"No increase of serum autoantibodies during therapy with recombinant human interferon-beta1a in relapsing-remitting multiple sclerosis","volume":"96","author":"Colosimo","year":"1997","journal-title":"Acta Neurol. Scand."},{"key":"10.1016\/j.neulet.2015.08.054_bib0080","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1212\/WNL.33.11.1444","article-title":"Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS)","volume":"33","author":"Kurtzke","year":"1983","journal-title":"Neurology"},{"key":"10.1016\/j.neulet.2015.08.054_bib0085","doi-asserted-by":"crossref","first-page":"3143","DOI":"10.1161\/circ.106.25.3143","volume":"106","author":"National Cholesterol Education Program (NCEP)","year":"2002","journal-title":"Circulation"},{"key":"10.1016\/j.neulet.2015.08.054_bib0090","doi-asserted-by":"crossref","first-page":"e39","DOI":"10.1161\/CIRCULATIONAHA.105.548495","article-title":"Antiphospholipid antibodies","volume":"112","author":"Misita","year":"2005","journal-title":"Circulation"},{"key":"10.1016\/j.neulet.2015.08.054_bib0095","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1053\/sarh.2002.28303","article-title":"Viral infections and antiphospholipid antibodies","volume":"31","author":"Uthman","year":"2002","journal-title":"Semin. Arthritis Rheum."},{"key":"10.1016\/j.neulet.2015.08.054_bib0100","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1002\/ana.410440408","article-title":"A subgroup of multiple sclerosis patients with anticardiolipin antibodies and unusual clinical manifestations: do they represent a new nosological entity?","volume":"44","author":"Karussis","year":"1998","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.neulet.2015.08.054_bib0105","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1212\/WNL.40.8.1181","article-title":"Cerebrovascular and neurologic disease associated with antiphospholipid antibodies: 48 cases","volume":"40","author":"Levine","year":"1990","journal-title":"Neurology"},{"key":"10.1016\/j.neulet.2015.08.054_bib0110","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1093\/rheumatology\/keh532","article-title":"Multiple sclerosis, neuropsychiatric lupus and antiphospholipid syndrome: where do we stand?","volume":"44","author":"Ferreira","year":"2005","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.neulet.2015.08.054_bib0115","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1055\/s-0037-1616239","article-title":"Annexins: key regulators of haemostasis, thrombosis, and apoptosis","volume":"86","author":"Reutelingsperger","year":"2001","journal-title":"Thromb. Haemost."},{"key":"10.1016\/j.neulet.2015.08.054_bib0120","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1177\/0961203310361485","article-title":"The annexin A5-mediated pathogenic mechanism in the antiphospholipid syndrome: role in pregnancy losses and thrombosis","volume":"19","author":"Rand","year":"2010","journal-title":"Lupus"},{"key":"10.1016\/j.neulet.2015.08.054_bib0125","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1055\/s-0038-1651585","article-title":"The effect of heparin and annexin V on fibrin accretion after injury in the jugular vein of rabbits","volume":"69","author":"Van Ryn McKenna","year":"1993","journal-title":"Thromb. Haemost."},{"key":"10.1016\/j.neulet.2015.08.054_bib0130","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1161\/01.ATV.14.5.824","article-title":"ANV inhibits the procoagulant activity of matrices of TNF-stimulated endothelium under flow conditions","volume":"14","author":"Van Heerde","year":"1994","journal-title":"Arterioscler. Thromb."},{"key":"10.1016\/j.neulet.2015.08.054_bib0135","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.1182\/blood.V92.5.1652","article-title":"Antiphospholipid antibodies accelerate plasma coagulation by inhibiting annexin-V binding to phospholipids: a lupus procoagulant phenomenon","volume":"5","author":"Rand","year":"1998","journal-title":"Blood"},{"key":"10.1016\/j.neulet.2015.08.054_bib0140","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1016\/j.autrev.2011.04.007","article-title":"Anti-annexins autoantibodies: their role as biomarkers of autoimmune diseases","volume":"10","author":"Iaccarino","year":"2011","journal-title":"Autoimmun. Rev."},{"key":"10.1016\/j.neulet.2015.08.054_bib0145","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/1477-9560-7-13","article-title":"Annexin V and anti-annexin V antibodies: two interesting aspects in acute myocardial infarction","volume":"7","author":"Shojaie","year":"2009","journal-title":"Thromb. J."},{"key":"10.1016\/j.neulet.2015.08.054_bib0150","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1179\/1743132812Y.0000000077","article-title":"Arterial, venous and other vascular risk factors in multiple sclerosis","volume":"34","author":"Karmon","year":"2012","journal-title":"Neurol. Res."},{"key":"10.1016\/j.neulet.2015.08.054_bib0155","doi-asserted-by":"crossref","first-page":"449","DOI":"10.2165\/00023210-200721060-00002","article-title":"Effect of HMG-CoA reductase inhibitors on beta-amyloid peptide levels: implications for Alzheimer\u2019s disease","volume":"21","author":"H\u00f6glund","year":"2007","journal-title":"CNS Drugs"},{"key":"10.1016\/j.neulet.2015.08.054_bib0160","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1186\/1741-7015-5-20","article-title":"Simvastatin is associated with a reduced incidence of dementia and Parkinson\u2019s disease","volume":"5","author":"Wolozin","year":"2007","journal-title":"BMC Med."},{"key":"10.1016\/j.neulet.2015.08.054_bib0165","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1016\/j.tins.2011.06.005","article-title":"Emerging roles for cholesterol in Huntington\u2019s disease","volume":"34","author":"Valenza","year":"2011","journal-title":"Trends Neurosci."},{"key":"10.1016\/j.neulet.2015.08.054_bib0170","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1242\/dmm.010124","article-title":"Dysregulation of cholesterol balance in the brain: contribution to neurodegenerative diseases","volume":"5","author":"Vance","year":"2012","journal-title":"Dis. Model Mech."},{"key":"10.1016\/j.neulet.2015.08.054_bib0175","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1056\/NEJMra1112830","article-title":"The pathogenesis of the antiphospholipid syndrome","volume":"368","author":"Giannakopoulos","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.neulet.2015.08.054_bib0180","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1161\/ATVBAHA.114.304342","article-title":"Induction of dendritic cell-mediated T-cell activation by modified but not native low-density lipoprotein in humans and inhibition by annexin a5: involvement of heat shock proteins","volume":"35","author":"Liu","year":"2015","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.neulet.2015.08.054_bib0185","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1016\/j.bbamcr.2010.09.015","article-title":"Annexin A6-linking Ca(2+) signaling with cholesterol transport","volume":"1813","author":"Enrich","year":"2011","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.neulet.2015.08.054_bib0190","doi-asserted-by":"crossref","first-page":"2292","DOI":"10.1182\/blood-2009-04-213520","article-title":"Hydroxychloroquine protects the annexin A5 anticoagulant shield from disruption by antiphospholipid antibodies: evidence for a novel effect for an old antimalarial drug","volume":"115","author":"Rand","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.neulet.2015.08.054_bib0195","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1001\/archneur.55.9.1248","article-title":"Effectiveness of chloroquine and hydroxychloroquine in treating selected patients with sarcoidosis with neurological involvement","volume":"55","author":"Sharma","year":"1998","journal-title":"Arch. Neurol."},{"key":"10.1016\/j.neulet.2015.08.054_bib0200","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1002\/art.21039","article-title":"Systemic lupus erythematosus in three ethnic groups: XVI. Association of hydroxychloroquine use with reduced risk of damage accrual","volume":"52","author":"Fessler","year":"2005","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.neulet.2015.08.054_bib0205","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1002\/art.10228","article-title":"Treatment of rheumatoid arthritis with methotrexate and hydroxychloroquine, methotrexate and sulfasalazine, or a combination of the three medications: results of a two-year, randomized, double-blind, placebo-controlled trial","volume":"46","author":"O'Dell","year":"2002","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.neulet.2015.08.054_bib0210","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1016\/j.cgh.2012.08.038","article-title":"Low-dose hydroxychloroquine is as effective as phlebotomy in treatment of patients with porphyria cutanea tarda","volume":"10","author":"Singal","year":"2012","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"10.1016\/j.neulet.2015.08.054_bib0215","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1185\/03007995.2014.909393","article-title":"Efficacy and safety of hydroxychloroquine in the treatment of type 2 diabetes mellitus: a double blind, randomized comparison with pioglitazone","volume":"30","author":"Pareek","year":"2014","journal-title":"Curr. Med. Res. Opin."}],"container-title":["Neuroscience Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304394015301245?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304394015301245?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,9,7]],"date-time":"2020-09-07T22:56:25Z","timestamp":1599519385000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0304394015301245"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,10]]},"references-count":43,"alternative-id":["S0304394015301245"],"URL":"https:\/\/doi.org\/10.1016\/j.neulet.2015.08.054","relation":{},"ISSN":["0304-3940"],"issn-type":[{"value":"0304-3940","type":"print"}],"subject":[],"published":{"date-parts":[[2015,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Anti-annexin antibodies, cholesterol levels and disability in multiple sclerosis","name":"articletitle","label":"Article Title"},{"value":"Neuroscience Letters","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neulet.2015.08.054","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier Ireland Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}